News

Review study evaluates botulinum for treating excessive drooling

Botulinum toxin was found to be relatively safe and effective for treating excessive drooling in people with Parkinson’s disease, according to a recent systematic review and meta-analysis of previous clinical trials. While side effects usually were mild, the researchers believe larger and longer studies are needed to establish the…

Healthy adult dosing begins in Phase 1 trial of HL192 for Parkinson’s

A first healthy volunteer has been dosed in a Phase 1 clinical trial assessing the safety and tolerability of HL192, an investigational therapy for Parkinson’s disease. The treatment, given orally, is designed to activate Nurr1, a key protein that regulates the development and maintenance of dopaminergic neurons. These nerve…

ParkinSex, APDA guide for intimacy, honored by healthcare industry

The American Parkinson’s Disease Association (APDA) received three MM+M awards, including the titanium Best in Show, for its ParkinSex guide to help people with Parkinson’s disease and their partners retain sexual intimacy. Now in its 20th year, the MM+M Awards recognize creativity and effectiveness in…

$5M NIH grant will advance study of how brain regulates movement

A five-year project funded by a $5 million National Institutes of Health (NIH) research grant will study how the brain regulates movements, by allowing people with Parkinson’s disease to play video games during brain surgeries. The goal, according to researchers, is to obtain information that can be applied to…

IRLAB ramps up for mesdopetam Phase 3 program in Parkinson’s

IRLAB Therapeutics is taking steps in preparation for a Phase 3 clinical program of mesdopetam, an experimental medicine for the treatment of levodopa-induced dyskinesia in Parkinson’s disease. The Swedish company is consulting with two advisors, Clintrex and ProPharma Group, to gather the documentation needed to request…

3D brain model will be used in pursuit of therapies

Stem Pharm and Verge Genomics are teaming up to develop a 3D brain model of Parkinson’s disease that uses advanced computational tools to validate new therapeutic candidates. The collaboration will leverage Stem Pharm’s human-derived “mini-brains” that model inflammation of the brain — neuroimmune organoids — and Verge’s…